Vimarsana
Biggest News Aggregation in the World

Filippo Petti News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Filippo Petti. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Filippo Petti Today - Breaking & Trending Today

Leucid Bio Appoints Filippo Petti as Chief Executive Officer - Vimarsana News

Leucid Bio Appoints Filippo Petti as Chief Executive Officer

/PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a biotech company pursuing a differentiated approach to develop next generation Chimeric Antigen...

Celyad Oncology : Listed limited liability company Rue Edouard Belin, 2 1435 Mont-Saint-Guibert - Form 6-K - Vimarsana News

Celyad Oncology : Listed limited liability company Rue Edouard Belin, 2 1435 Mont-Saint-Guibert - Form 6-K

Listed limited liability company Rue Edouard Belin, 2 1435 Mont-Saint-Guibert LER Nivelles 0891.118.115 ... | April 4, 2023

Celyad Oncology SA: Celyad Oncology: Letter to Shareholders - Vimarsana News

Celyad Oncology SA: Celyad Oncology: Letter to Shareholders

Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD): Dear Shareholder, 2022 has been a crossroad year for Celyad Oncology (the "Company"), with important changes and

Celyad Oncology: Letter to Shareholders Seite 1 - Vimarsana News

Celyad Oncology: Letter to Shareholders Seite 1

01.03.2023 - Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD): Dear Shareholder, 2022 has been a crossroad year for Celyad Oncology (the “Company”), with important changes and turning points. Whilst our clinical programs had clear ... Seite 1

Celyad Oncology SA - Letter to Shareholders - Vimarsana News

Celyad Oncology SA - Letter to Shareholders

MONT-SAINT-GUIBERT, Belgium, Feb. 28, 2023 -- The following is a statement by Celyad Oncology: Dear Shareholder, 2022 has been a crossroad year for Celyad Oncology , with important changes... | February 28, 2023